ABSTRACT
Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy. Alendronate, however, can be given as a once-weekly dose, whereas risedronate is not yet available in this dosage form. On the other hand, alendronate is not approved for preventing glucocorticoid-induced osteoporosis, whereas risedronate carries this indication.
Footnotes
↵* The author is a consultant for Merck and has received grant or research support from the Merck, Lilly, Pfizer, Takeda, and Novartis companies.
- Copyright © 2001 The Cleveland Clinic Foundation. All Rights Reserved.